- Previous Close
7.48 - Open
7.52 - Bid 7.51 x 400
- Ask 7.62 x 800
- Day's Range
7.49 - 7.63 - 52 Week Range
6.85 - 13.55 - Volume
2,363,087 - Avg. Volume
14,356,854 - Market Cap (intraday)
9.024B - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-0.53 - Earnings Date May 8, 2025
- Forward Dividend & Yield 0.48 (6.42%)
- Ex-Dividend Date Mar 10, 2025
- 1y Target Est
12.03
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
www.viatris.com32,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: VTRS
View More
Performance Overview: VTRS
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VTRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VTRS
View MoreValuation Measures
Market Cap
8.93B
Enterprise Value
22.14B
Trailing P/E
--
Forward P/E
3.47
PEG Ratio (5yr expected)
0.13
Price/Sales (ttm)
0.61
Price/Book (mrq)
0.48
Enterprise Value/Revenue
1.50
Enterprise Value/EBITDA
7.85
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.30%
Return on Assets (ttm)
2.49%
Return on Equity (ttm)
-3.24%
Revenue (ttm)
14.74B
Net Income Avi to Common (ttm)
-634.2M
Diluted EPS (ttm)
-0.53
Balance Sheet and Cash Flow
Total Cash (mrq)
1.09B
Total Debt/Equity (mrq)
76.77%
Levered Free Cash Flow (ttm)
6.55B
Research Analysis: VTRS
View MoreResearch Reports: VTRS
View MoreGenerics Industry: India Celebrates Pharmaceutical Tariffs Exemption but Uncertainty Remains High
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
RatingPrice TargetLowering earnings estimate for 2025
Viatris Inc., based in Pennsylvania, is a specialty and generic drug company formed in 2020 through the combination of Pfizer's Upjohn business and Mylan N.V. The shares are a component of the S&P 500. The company has 32,000 employees. Viatris has scientific, manufacturing, distribution, and regulatory expertise, and serves patients in more than 165 countries and territories. The company's portfolio includes more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both noncommunicable and infectious diseases. Its products include complex generic and branded medicines and over-the-counter consumer products.
RatingPrice TargetSome Irish Green Peeking Out: The markets have mostly turned higher at midday,
Some Irish Green Peeking Out: The markets have mostly turned higher at midday, though the Nasdaq is still struggling. Retail Sales for February came in lighter than expected, consistent with recent worries that the US economy is slowing. The yield on the 10-year Treasury note is at 4.19%. Oil is at $67 per barrel. Bitcoin is near $83,000
Viatris Earnings: Facility Inspection Throws Wrench in Business Stability and Sinks Shares
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
RatingPrice Target